STAT July 26, 2024
Good morning. We’ve made it to the end of the week! I don’t know about you, but it’s felt like an especially long week for me. It’s probably cause of all the news that we will get into right now.
The need-to-know this morning
- Bristol Myers Squibb reported second-quarter earnings.
EMA issues negative opinion on Leqembi
From STAT’s Andrew Joseph: European regulators said today that Leqembi, the Eisai and Biogen Alzheimer’s medicine that’s approved in the U.S. and a number of other countries, should be rejected. In its statement, the European Medicines Agency said the benefits of Leqembi did not outweigh the risks associated with its class of therapies, namely a condition called ARIA that involves brain swelling...
Today's Sponsors
Today's Sponsor
Topics: Medical Devices